The IPO of OS Therapies Incorporated is likely to generate interest among investors, especially given its focus on developing treatments for osteosarcoma and other solid tumors. The set price of $4.00 per share and the insider lock-up period ending on January 27, 2025, are key details that could influence short-term trading activity.